IQVIA (NYSE:IQV) Shares Acquired Sen. Markwayne Mullin

Senator Markwayne Mullin (R-Oklahoma) recently bought shares of IQVIA Holdings Inc. (NYSE:IQV). In a filing disclosed on February 27th, the Senator disclosed that they had bought between $15,001 and $50,000 in IQVIA stock on February 13th.

Senator Markwayne Mullin also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Amazon.com (NASDAQ:AMZN) on 2/13/2025.
• Sold $15,001 – $50,000 in shares of Honeywell International (NASDAQ:HON) on 2/13/2025.
• Sold $15,001 – $50,000 in shares of Brick (TSE:BRK) on 2/13/2025.
• Sold $100,001 – $250,000 in shares of Vanguard Materials ETF (NYSEARCA:VAW) on 2/13/2025.
• Purchased $50,001 – $100,000 in shares of Microsoft (NASDAQ:MSFT) on 2/13/2025.
• Sold $15,001 – $50,000 in shares of Constellation Brands (NYSE:STZ) on 2/13/2025.
• Purchased $50,001 – $100,000 in shares of LPL Financial (NASDAQ:LPLA) on 2/13/2025.
• Purchased $15,001 – $50,000 in shares of TJX Companies (NYSE:TJX) on 2/13/2025.
• Sold $50,001 – $100,000 in shares of Advanced Micro Devices (NASDAQ:AMD) on 2/13/2025.
• Purchased $50,001 – $100,000 in shares of Accenture (NYSE:ACN) on 2/13/2025.

IQVIA Stock Performance

NYSE:IQV opened at $188.89 on Friday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a fifty-two week low of $184.66 and a fifty-two week high of $261.73. The stock has a market cap of $33.26 billion, a PE ratio of 25.19, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48. The firm’s fifty day simple moving average is $199.13 and its 200-day simple moving average is $214.80.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Institutional Trading of IQVIA

A number of institutional investors and hedge funds have recently bought and sold shares of IQV. Smith Group Asset Management LLC acquired a new stake in IQVIA in the fourth quarter valued at approximately $1,616,000. Simplify Asset Management Inc. grew its position in IQVIA by 67.8% in the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock valued at $2,284,000 after acquiring an additional 3,894 shares in the last quarter. Nordea Investment Management AB grew its position in IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares in the last quarter. Hickory Asset Management Inc. acquired a new stake in IQVIA in the fourth quarter valued at approximately $941,000. Finally, Fifth Third Bancorp grew its position in IQVIA by 13.0% in the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock valued at $2,590,000 after acquiring an additional 1,521 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In related news, Director John G. Danhakl purchased 1,275 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The stock was acquired at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the transaction, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Stephens began coverage on shares of IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a report on Monday, February 10th. William Blair restated an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Finally, Bank of America reduced their target price on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Four investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $251.22.

About Senator Mullin

Markwayne Mullin (Republican Party) is a member of the U.S. Senate from Oklahoma. He assumed office on January 11, 2023. His current term ends on January 3, 2027. Mullin (Republican Party) ran in a special election to the U.S. Senate to represent Oklahoma. He won in the special general election on November 8, 2022. Mullin is a member of the Cherokee Nation and one of four Native American members of the 116th Congress. At the age of 20, Mullin took over his father’s plumbing business. He is also a former professional mixed martial artist. Markwayne Mullin graduated from Stilwell High School. Mullin earned an associate degree in construction technology from Oklahoma State University Institute of Technology. His career experience includes owning and founding multiple businesses.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.